Biography
Dr. Thomas E. Serena MD FACS FACHM MAPWCA, Founder and Medical Director of The SerenaGroup®, a family of wound, hyperbaric and research companies, is a Phi Beta Kappa graduate of The College of William and Mary and Penn State Medical School. He completed his residency in Surgery at The Milton S. Hershey Medical Center with additional year of training in Plastic and Reconstructive Surgery at Southern Illinois University. To date he has opened and operates wound care centers across the United Sates and globally. Dr. Serena has been the lead or Principal investigator in over 100 clinical trials, including gene therapy for critical limb ischemia, antimicrobial dressings, growth factors, topical and parenteral antibiotics and CTP therapy. He founded the first wound healing cooperative research group that produced more than 12 manuscripts in 2016 alone. In 2011 he developed a diagnostic technique that now bears his name (The Serena Technique©). He holds numerous patents on wound care devices and dressings. He is recognized internationally as an expert in the field of wound healing: He has more than 200 published papers and has given more than 1000 invited lectures throughout the world. He has published three medical textbooks and authored numerous book chapters. He has been a member of the Board of Directors of the Wound Healing Society and served two terms on the board of the Association for the Advancement of Wound Care (AAWC) and is now the President. He has also been Vice-President of the American College of Hyperbaric Medicine and President of the American Professional Wound Care Association. Dr. Serena has done extensive medical relief work with Health Volunteers Overseas and served as chairman of the AAWC Global Volunteers/HVO Steering Committee until 2016. In 2016 in partnership with HEAL Foundation he opened a wound clinic in Ho Chi Minh, Vietnam. Outside of wound healing, he consulted for the government of Rwanda on AIDS prevention research.
Research Interest
wound and hyperbaric research
Biography
Dr Ryan Moseley graduated from Swansea University with a BSc (Honours) Degree in Biochemistry. Later, he obtained his PhD from the School of Dentistry, University of Wales College of Medicine, examining the role of oxidative stress in periodontal disease. Dr Moseley continues his research at Cardiff University, where he is currently a Reader in Tissue Repair and Director of the CITER MSc Programme in Tissue Engineering. Dr. Moseley’s research focusses on the mechanisms underlying dermal and oral wound healing during health and disease; and the development of stem cell-, biomaterial- and pharmaceutical-based strategies to address impaired healing in these tissues.
Research Interest
Dermal, oral wound healing, stem cell-, biomaterial

Wei Li
Professor and Director
Department of Dermatology and the Norris Comprehensive Cancer Center
USA
Biography
After receiving his college education in Biology Major from Xinjiang University, People’s Republic of China, Dr. Li came to the US in 1985. He received MS degree in 1988 and PhD degree in 1991 from the Department of Developmental Biology and Cancer at the Albert Einstein College of Medicine, Bronx, New York City. Following a two-year post-doctoral/instructor fellowship with Dr. Joseph Schlessinger (Professor and Chairman, currently at Yale University Medical Center), he joined the faculty of the Ben May Institute for Cancer Research at the University of Chicago in the fall of 1993 as an Assistant Professor. He was recruited to University of Southern California (USC) Keck School of Medicine in 1999 and rose to full professor in 2006. He is currently a Professor and Director of the GMCB Graduate Program at USC Keck School of Medicine. His research interest focuses wound healing and cancer cell invasion. His laboratory is the first to identify the important role for the SECRETED form of heat shock protein-90 (Hsp90) in skin wound healing. He is the principle author of more than 80 peer-reviews publications in first-rate biomedical journals.
Research Interest
wound healing and cancer cell invasion